-
Electronic (PDF)
-
Site License
-
Enterprisewide
Pharmalink AB - Product Pipeline Review - Q4 2010
GlobalData, November 2010, Pages: 31
Pharmalink AB – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Pharmalink AB - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Pharmalink AB - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pharmalink AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pharmalink AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pharmalink AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Pharmalink AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pharmalink AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pharmalink AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pharmalink AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pharmalink AB and identify potential opportunities in those areas.
List of Tables
List of Figures
Pharmalink AB Snapshot
Pharmalink AB Overview
Key Information
Key Facts
Pharmalink AB – Research and Development Overview
Key Therapeutic Areas
Pharmalink AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pharmalink AB – Pipeline Products Glance
Pharmalink AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Pharmalink AB – Drug Profiles
Busulipo
Product Description
Mechanism of Action
R&D Progress
Nefecon
Product Description
Mechanism of Action
R&D Progress
LI-49
Product Description
Mechanism of Action
R&D Progress
Pharmalink AB – Pipeline Analysis
Pharmalink AB – Pipeline Products by Therapeutic Class
Pharmalink AB Pipeline Products By Target
Pharmalink AB – Pipeline Products by Route of Administration
Pharmalink AB – Pipeline Products by Molecule Type
Pharmalink AB – Recent Pipeline Updates
Pharmalink AB – Locations And Subsidiaries
Head Office
Recent Developments
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon
Apr 14, 2008: Pharmalink Reports The Approval Of Key Patent For Chemotherapy Drug Busulipo
Apr 14, 2008: Pharmalink Reports The Approval Of Key Patent For Chemotherapy Drug Busulipo
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon
Oct 26, 2006: Japanese Patent granted for Pharmalink AB's Nefecon
Oct 26, 2006: Japanese Patent granted for Pharmalink AB's Nefecon
Financial Deals Landscape
Pharmalink AB, Deals Summary, 2004 to 2010
Pharmalink AB Detailed Deal Summary
Venture Financing
Pharmalink Secures $1 Million In Venture Financing
West Pharmaceutical Services Enters Into Co-Devlopment Agreement With Pharmalink
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
